Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy.

The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and enhance the effects of current standard-of-care therapies. Engineered for systemic delivery, Theriva’s oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment (intratumoral, intravitreal).